A New Paradigm in Drug Development - The mission of Bio-Path is to make its neutral lipid delivery the standard delivery technology for antisense therapeutics in the pharmaceutical industry.
Liposomal Grb-2 Clinical Trial

Bio-Path completed six cohorts of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers. The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. A maximum tolerated dose has yet to be reached. The clinical trial is being conducted at the MD Anderson Cancer Center.

The Company expects to start its Phase II program by the end of 2014, which will include three Phase II clinical trials of Liposomal Grb-2 salvage therapy in combination with frontline therapy in three different leukemia disease types: AML, CML and MDS.

Latest News

Nov 17, 2014
Bio-Path Holdings Reports Third Quarter 2014 Operational and Financial Results

Nov 13, 2014
Bio-Path Holdings Proxy Statement (Schedule 14A)

Nov 6, 2014
Bio-Path Holdings Appoints Amy P. Sing, M.D. to its Board of Directors

Oct 16, 2014
NASDAQ Release: Bio-Path Holdings, Inc. to Ring The NASDAQ Stock Market Closing Bell (Friday, Oct. 17, 2014 at 3:45 - 4:00 PM Eastern Time)